Specific proposals and targets top the universities’ desired priorities

What are the universities’ expectations for the update of the national life science strategy? Life Science Sweden posed the question to representatives from Kar...

”Information security must become part of the Swedish life science strategy”

Sweden needs knowledge security to stand strong in the global competition, writes Björn Ursing in an opinion article.

Emerson

No longer afraid of the dentist.

Teaching robot with piezo technology

She is CSL Behring's new Nordic General Manager

Since the beginning of january, Helena Bragd is the new Nordic General Manager for the biotech company CSL Behring and CEO of CSL Behring AB.

The Top 10 Challenges Facing Laboratories Today

Navigating the Laboratory Automation Landscape

Large study: The benefits and risks of obesity medications

Medications such as Ozempic can reduce the risk of a range of different diseases and health conditions but also increase the risk of others. This is according t...

Rapid development in blood analysis – “Sweden is leading the race”

Thousands of analytical tests using just one single drop of blood. What was revealed as a hoax just a few years ago is now a reality, according to KTH professor...

Conference recordings now available

Don't miss out on insights from leading experts.

Biosimilars bring price pressure, but are they sufficiently used?

When biosimilars were introduced just over 16 years ago, hopes were raised that they would give many more patients access to effective but otherwise extremely e...

Quality solutions for medical device R&D applications

From R&D to the quality assurance of series production in medical device manufacturing.

Life Science Sweden´s international issue is on its way

A new issue of Life Science Sweden is on its way to print, packed with news, interviews and reports.

Webinar: Can AI replace humans in pharmacovigilance?

The webinar will explore how AI can transform pharmacovigilance by enhancing efficiency, reducing errors, and addressing challenges such as software costs, data...

Eli Lilly to build a USD 2.5-billion plant in Germany

US-based Eli Lilly is planning a huge investment of USD 2.5 billion, equivalent to around SEK 26.5 billion, in a new production facility in Alzey, Germany.

Final assembly inspection of medical plastics

Technical paper by ZEISS Medical Industry Solutions.

Total pipeline of pharmaceutical companies reaches a record high – 22,921 medicines are currently being developed

Despite the difficult economic times, pharmaceutical companies have never developed as many new drugs as now.

Webinar: Support Trial Patients Transitioning to the Commercial Space

Register for expert insights on supporting Phase III clinical trial patients post-approval and read our blog on advanced Patient Assistance Programs.

Life science trends 2025 – The economy

Upcoming patent expirations are driving pharmaceutical companies to acquire in 2025. In Sweden, we may be on our way to brighter times and fewer bankruptcies. T...

Rising interest in CRISPR treatments

Treatments using CRISPR technology are emerging as one of the hottest medical trends in the United States – and the FDA is doing its best to promote the development.

The key to successful collaboration between industry and academia

Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?

Acquisition of consulting company Key2Compliance

The Swedish company Key2Compliance, offering services in fields such as pharma and Medtech, has been acquired by German GBA Group.

Quality Assurance for the Highest Medical Standards

Metrology Solutions for Medical Components.

Automate E2E Image Analysis Pipelines

ZEISS arivis Pro - Your End-to-End Scientific Image Analysis Software.

Ytterligare läkemedelskandidat mot Alzheimers droppas

Ett litet schweiziskt biotechbolag avbryter en fas II-studien med sin läkemedelskandidat mot Alzheimers sjukdom. Beskedet kommer inte långt efter att Biogen och...